Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus
Keywords:Delphi Panel, European Myeloma Network, Monoclonal antibodies, Multiple myeloma
Introduction: The objective of this study was to understand the potential use of single agents and drug combinations in multiple myeloma (MM) across treatment lines in the years 2021 and 2023.
Methods: The method used was Delphi Panel Method survey, administered to European Myeloma Network (EMN) Italy Working Group centres. Future treatments were identified assessing all available web-based information sources, including therapies (single drugs or combinations) with strong evidence of efficacy, likely to be on the Italian market in 2021 and 2023. Participants were asked to report on the likelihood of prescription for MM therapies, across treatment lines.
Results: Across the 15 centres taking part in the survey, about 890 patients per year are forecasted to receive a new diagnosis of MM. In 2021, the Panel forecasted 66% of 1L-TE (transplant eligible) patients will be treated with bortezomib-thalidomide-dexamethasone (VTD) and 32% of patients with daratumumab-bortezomib-thalidomide-dexamethasone (DVTd), with a substantial decrease of VTD (15%) and a marked increase of DVTd (81%) forecasted for 2023. The 2L and 3L R(lenalidomide)-based combination treatments are expected to drop and will likely be substituted by a steep increase in P(pomalidomide)-based regimes (from 7% to 23%). On the contrary, in 3L treatment, all combination therapies (with the exception of IsaPd – isatuximab-pomalidomide-dexamethasone) are expected to lose market share in favour of the most recent new therapies.
Conclusions: Expert Panel agrees that many different new drugs and combinations will be used in MM, with different mechanisms of action, both at diagnosis and in subsequent phases of the disease, with a corresponding decline of the drugs currently used.
AIOM Associazione Italiana Oncologia Medica. Linee Guida Mieloma. Edizione 2017 Online http://media.aiom.it/userfiles/files/doc/LG/2017_LGAIOM_Mieloma.pdf (accessed November 2020).
Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3(1):17046. https://doi.org/10.1038/nrdp.2017.46 PMID:28726797
Abramson HN. B-cell maturation antigen (BCMA) as a target for new drug development in relapsed and/or refractory multiple myeloma. Int J Mol Sci. 2020;21(15):5192. https://doi.org/10.3390/ijms21155192 PMID:32707894
European Medicines Agency Sarclisa – isatuximab. Online https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa (accessed November 2020).
Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985-1005. https://doi.org/10.1038/s41375-020-0734-z PMID:32055000
Acone B, Urbani A. The Delphi Method: The methodology and its application. JHA. 2018;S1(S1):9-14. https://doi.org/10.19198/JHA31464
Trevelyan EG, Robinson N. Delphi methodology in health research: how to do it? Eur J Integr Med. 2015;7(4):423-428. https://doi.org/10.1016/j.eujim.2015.07.002
Hsu CC, Sandford BA. The Delphi Technique: making sense of consensus. Pract Assess Res Eval. 2007;12(10). https://doi.org/10.7275/pdz9-th90 (accessed November2020).
Dalkey N, Helmer O. An experimental application of the Delphi Method to the use of experts. Manage Sci. 1963;9(3):458-467. https://doi.org/10.1287/mnsc.9.3.458
Kerlinger FN. Foundations of behavioural research. New York: Holt, Rinehart, and Winston, Inc 1973.
Linstone HA, Turoff M. The Delphi method: techniques and applications. Reading, MA: Addison-Wesley Publishing Company 1975.
Dalkey NC, Rourke DL. Experimental assessment of Delphi procedures with group value judgments. In: Dalkey NC, Rourke DL, Lewis R, et al, eds. Studies in the quality of life: Delphi and decision-making. Lexington, MA: Lexington Books 1972; 55-83.
How to Cite
Authors contributing to Global & Regional Health Technology Assessment agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.